CBIO vs LXRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

CBIO

45.7
AI Score
VS
LXRX Wins

LXRX

53.1
AI Score

Investment Advisor Scores

CBIO

46score
Recommendation
HOLD

LXRX

53score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CBIO LXRX Winner
Revenue 1.04M 1.26M LXRX
Net Income -48.12M -25.30M LXRX
Net Margin -4631.4% -2004.4% LXRX
Operating Income -51.09M -25.68M LXRX
ROE -29.5% -20.6% LXRX
ROA -26.3% -8.5% LXRX
Total Assets 182.76M 297.67M LXRX
Cash 171.59M 62.89M CBIO
Current Ratio 9.66 2.22 CBIO

Relative Price Performance (Last 90 Days)

CBIO 1M: -15.3% · 3M: -35.3% LXRX 1M: -1.3% · 3M: +43.5%

Current Technical Phase

CBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.7%), weak momentum, RSI 39

RSI (14): 38.5 · Price: $14.47

LXRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.7% over 20 days), RSI 53

RSI (14): 53.3 · Price: $2.31

Fundamentals Snapshot

Metric CBIO LXRX
Market Cap
Forward P/E -4.9 -11.3
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 15.7%
Gross Margin 1.0% 0.9%
Operating Margin -23.8% 0.0%
EPS -5.97 -0.07
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, LXRX is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.